Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01537432
- Locations
- 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT01426789
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.